Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01325428
Registration number
NCT01325428
Ethics application status
Date submitted
28/03/2011
Date registered
29/03/2011
Date last updated
19/07/2016
Titles & IDs
Public title
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
Query!
Scientific title
An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer
Query!
Secondary ID [1]
0
0
2010-024454-10
Query!
Secondary ID [2]
0
0
1200.89
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Afatinib once daily (OD)
Treatment: Drugs - Vinorelbine Weekly
Experimental: Afatinib once daily (OD) - Patients receive afatinib monotherapy once daily until progression of their disease
Treatment: Drugs: Afatinib once daily (OD)
Patient to receive afatinib monotherapy until progression of their disease
Treatment: Drugs: Vinorelbine Weekly
Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part A: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).
Query!
Assessment method [1]
0
0
Tumour response was assessed separately for Part A and Part B according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The primary endpoint of this study was confirmed clinical benefit, as assessed by Stable Disease (SD) for at least 6 months (defined as >182 days), Partial Response (PR), or Complete Response (CR) according to RECIST version 1.1 (only confirmed responses were considered).
Query!
Timepoint [1]
0
0
This endpoint was assessed between the from first administration of trial medication in Part A and the earliest of PD, death or start of next treatment (either Part B combination therapy or new anti-cancer therapy) up to 929 days.
Query!
Primary outcome [2]
0
0
Part B: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).
Query!
Assessment method [2]
0
0
Tumour response was assessed separately for Part B according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The primary endpoint of this study was confirmed clinical benefit, as assessed by Stable Disease (SD) for at least 6 months (defined as >182 days), Partial Response (PR), or Complete Response (CR) according to RECIST version 1.1 (only confirmed responses were considered).
Query!
Timepoint [2]
0
0
This endpoint was recorded from first administration of trial medication in Part B until the earliest of PD, death or start of new anti-cancer therapy up to 929 days.
Query!
Secondary outcome [1]
0
0
Part A: Confirmed Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1).
Query!
Assessment method [1]
0
0
Objective response was defined on a patient level as a best response of CR or PR.
Query!
Timepoint [1]
0
0
This endpoint was recorded from first administration of trial medication until the earliest of disease progression, death or start of next treatment (either Part B combination therapy or new anti-cancer therapy) up to 929 days.
Query!
Secondary outcome [2]
0
0
Part B: Confirmed Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1).
Query!
Assessment method [2]
0
0
Objective response was defined on a patient level as a best response of CR or PR.
Query!
Timepoint [2]
0
0
This endpoint was recorded from first administration of trial medication in Part B and until the earliest of disease progression, death or start of new anti-cancer therapy up to 929 days.
Query!
Secondary outcome [3]
0
0
Part A: Unconfirmed Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1).
Query!
Assessment method [3]
0
0
Objective response was defined on a patient level as a best response of CR or PR.
Query!
Timepoint [3]
0
0
This endpoint was recorded from first administration of trial medication until the earliest of PD, death or start of next treatment (either Part B combination therapy or new anti-cancer therapy) up to 929 days.
Query!
Secondary outcome [4]
0
0
Part B: Unconfirmed Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1 ).
Query!
Assessment method [4]
0
0
Objective response was defined on a patient level as a best response of CR or PR.
Query!
Timepoint [4]
0
0
This endpoint was recorded from first administration of trial medication in Part B and until the earliest of PD, death or start of new anti-cancer therapy up to 929 days.
Query!
Secondary outcome [5]
0
0
Part A: Duration of Unconfirmed Objective Response.
Query!
Assessment method [5]
0
0
Objective Response (OR) was defined on a patient level as a best response of Complete Response (CR) or Partial Response (PR). Duration of objective response was measured from the time of first unconfirmed objective response to the time of progression or death (or date of censoring for Progression Free Survival (PFS)).
Query!
Timepoint [5]
0
0
From first drug administration until end of Part A, up to 929 days.
Query!
Secondary outcome [6]
0
0
Part B: Duration of Unconfirmed Objective Response.
Query!
Assessment method [6]
0
0
Objective response was defined on a patient level as a best response of CR or PR. Duration of objective response was measured from the time of first unconfirmed objective response to the time of progression or death (or date of censoring for PFS).
Query!
Timepoint [6]
0
0
From first drug administration until end of Part B, up to 929 days.
Query!
Secondary outcome [7]
0
0
Part A: Progression Free Survival.
Query!
Assessment method [7]
0
0
PD was evaluated according to the RECIST version 1.1. For patients with a known date of progression (or death), PFS was the earlier of date of progression or death - date of first administration + 1. The date of progression and date of first administration referred to the respective part of the study A.
Query!
Timepoint [7]
0
0
From first drug administration until end of Part A, up to 713 days.
Query!
Secondary outcome [8]
0
0
Part B: Progression Free Survival.
Query!
Assessment method [8]
0
0
PD was evaluated according to the RECIST version 1.1. For patients with a known date of progression (or death), PFS was the earlier of date of progression or death - date of first administration + 1. The date of progression and date of first administration referred to the respective part of the study B.
Query!
Timepoint [8]
0
0
From first drug administration until end of Part B, up to 230 days.
Query!
Secondary outcome [9]
0
0
Progression Free Survival Over the Whole Sudy.
Query!
Assessment method [9]
0
0
PD was evaluated according to the RECIST version 1.1. Number of days from the start of monotherapy to the date of second PD.
Query!
Timepoint [9]
0
0
From first drug administration until end of study, up to 700 days.
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
1. Female patients >=18 years with proven diagnosis of HER2-overexpressing,
histologically confirmed breast cancer
2. Locally advanced or metastatic disease
3. Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation
Criteria for Solid Tumours version 1.1)
4. For trastuzumab pre-treated patients, must have failed prior trastuzumab treatment
5. Investigator-confirmed diagnosis of Inflammatory Breast Cancer
6. Must have biopsiable disease
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
1. Prior treatment with HER2-targeted small molecules or antibodies other than
trastuzumab (which must have been given in the trastuzumab-failure study population)
2. Must not have received prior vinorelbine treatment
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
26
Query!
Recruitment in Australia
Recruitment state(s)
VIC,WA
Query!
Recruitment hospital [1]
0
0
1200.89.61002 Boehringer Ingelheim Investigational Site - East Bentleigh
Query!
Recruitment hospital [2]
0
0
1200.89.61003 Boehringer Ingelheim Investigational Site - Perth
Query!
Recruitment postcode(s) [1]
0
0
- East Bentleigh
Query!
Recruitment postcode(s) [2]
0
0
- Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
North Carolina
Query!
Country [3]
0
0
Hong Kong
Query!
State/province [3]
0
0
Hong Kong
Query!
Country [4]
0
0
Korea, Republic of
Query!
State/province [4]
0
0
Seoul
Query!
Country [5]
0
0
Thailand
Query!
State/province [5]
0
0
Bangkok
Query!
Country [6]
0
0
Thailand
Query!
State/province [6]
0
0
Chiangmai
Query!
Country [7]
0
0
Thailand
Query!
State/province [7]
0
0
Hat-Yai, Songkhla
Query!
Country [8]
0
0
Tunisia
Query!
State/province [8]
0
0
Ariana
Query!
Country [9]
0
0
Tunisia
Query!
State/province [9]
0
0
Sousse
Query!
Country [10]
0
0
United Kingdom
Query!
State/province [10]
0
0
Bournemouth
Query!
Country [11]
0
0
United Kingdom
Query!
State/province [11]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The general aim of this study is to investigate the efficacy and safety of afatinib alone and
in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy
within this trial) as treatment in patients with HER2-overexpressing, locally advanced or
metastatic inflammatory breast cancer. The study will include patients who have and have not
failed prior trastuzumab treatment.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01325428
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01325428
Download to PDF